10 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital
In this article, we discuss 10 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.
Hedge Fund - Birchview Capital
Get Email AlertsMatthew Strobeck Bio, Returns, AUM, Net Worth
Manager biography is currently missing.
Fund Profile
Filing Period:
| Fund Name: | Birchview Capital |
| Manager | Matthew Strobeck |
| Portfolio Value | $133,413,992 |
| Change This QTR | +1042.03% |
Top 13F Holdings
Latest 13D & 13G Filings
| Symbol | Company | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2021-12-17 | ||||
| 2019-03-19 | ||||
| 2017-12-29 | ||||
| 2017-12-26 |
News, Interviews and Investor Letters
13D Filing: Birchview Capital and Yield10 Bioscience Inc. (YTEN)
Underwriting Agreement, dated as of December 19, 2017, by and between Yield10 Bioscience, Inc. and Ladenburg Thalmann & Co. Inc.
13G Filing: Birchview Capital and Soleno Therapeutics Inc (SLNO)
By signing below the Reporting Person certifies that, to the best of such person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with...
Birchview Capital's Top Healthcare Stock Picks
Birchview Capital is a Vermont-based biosciences-focused long/short equity hedge fund founded by Dr. Matthew Strobeck in 2014. Dr. Strobeck holds a Ph.D.
Celgene Corporation (CELG), Accelerate Diagnostics Inc (AXDX) and Metabolix, Inc. (MBLX) Among Birchview's Top Bioscience Picks
Dr. Matthew Strobeck's Birchview Capital has recently disclosed its equity holdings in a 13F filing with the SEC.
